ReviewCurrent oncology (Toronto, Ont.)2022
The Prediction of Survival after Surgical Management of Bone Metastases of the Extremities-A Comparison of Prognostic Models.
Review in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Artificial Intelligence for Detection and Characterisation of Bone Metastases on MRI: A Scoping Review.Cancers · 2026Review
- Cancer-specific survival patterns in patients with bone metastasis: a registry-based analysis of 13,742 patients.Scientific reports · 2026Article
- Article
- OPTIModel scoring for metastatic bone tumors: A data-driven tool for surgical planning and prognosis.Joint diseases and related surgery · 2026Article
- Validation of nine prognostic models in patients with bone metastases undergoing surgery.Journal of orthopaedic surgery and research · 2025Article
- Palliative care of proximal femur metastatic disease and osteolytic lesions: results following surgical and radiation treatment.BMC cancer · 2024Article
- Risk Factors for Early Postoperative Morbidity and Mortality following Extremity Metastatic Pathologic or Impending Fracture Fixation.International journal of surgical oncology · 2024Article
- Prognostic factors and real-life applicability of prognostic models for patients with bone metastases of carcinoma.Acta orthopaedica et traumatologica turcica · 2024Article
- Therapeutic approaches in patients with bone metastasis due to endometrial carcinoma - A systematic review.Journal of bone oncology · 2023Review
- Functional and Survival Outcomes of Patients following the Harrington Procedure for Complex Acetabular Metastatic Lesions.Current oncology (Toronto, Ont.) · 2022Article
- Treatment of Bone Metastasis.Current oncology (Toronto, Ont.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individualized survival prognostic models for symptomatic patients with appendicular metastatic bone disease are key to guiding clinical decision-making for the orthopedic surgeon. Several prognostic models have been developed in recent years; however, most orthopedic surgeons have not incorporated these models into routine practice. This is possibly due to uncertainty concerning their accuracy and the lack of comparison publications and recommendations. Our aim was to conduct a review and quality assessment of these models. A computerized literature search in MEDLINE, EMBASE and PubMed up to February 2022 was done, using keywords: "Bone metastasis", "survival", "extremity" and "prognosis". We evaluated each model's performance, assessing the estimated discriminative power and calibration accuracy for the analyzed patients. We included 11 studies out of the 1779 citations initially retrieved. The 11 studies included seven different models for estimating survival. Among externally validated survival prediction scores, PATHFx 3.0, 2013-SPRING and potentially Optimodel were found to be the best models in terms of performance. Currently, it is still a challenge to recommend any of the models as the standard for predicting survival for these patients. However, some models show better performance status and other quality characteristics. We recommend future, large, multicenter, prospective studies to compare between PATHfx 3.0, SPRING 2013 and OptiModel using the same external validation dataset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.